Innovation is a key aspect of WWIEM’s activity.  Translation of our research into innovative therapeutics to improve patient outcomes is central to our research endeavours.

Our approach to innovation is twofold:

• We engage and collaborate with the leading industrial partners in the biotechnology, pharma development and medical diagnostics industries;
• We support the creation of new companies that pursue our goal of improving patient outcomes.

Since 2015, we have developed more than 30 projects and collaborations with different biopharma industrial partners.  These projects demonstrate our engagement with industry and represent our commitment to be at the forefront of industrial developments in the biopharma sector.  Our industrial partners include, among others, GlaxoSmithKline, Pfizer, AstraZeneca, Novartis Pharma, Boehringer Ingelheim Pharma, Basilea Pharmaceutica, Randox Laboratories, Celerion, Novaliq; Novo Nordisk and F. Hoffmann-La Roche.

The Institute actively contributes to the success of spinout companies created by our researchers and provides access to our world-class facilities for the initial stages of the company.  New spinout companies include VacVersa.

Industrial collaborations and initiatives are supported by our Business Development Manager, Dr Macu Higueras (i.higueras@qub.ac.uk).